Seres Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Seres Therapeutics, Inc. (MCRB) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$18.45 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-08
- Seres Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$9.94M.
- Seres Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $12.38M.
- Seres Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$8.26M.
- Seres Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$12.64M, a 110.60% decline year-over-year.
- Seres Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$18.45M.
- Seres Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$19.39M.
- Seres Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$40.25M, a 135.77% decline from fiscal 2014.
- Seres Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $112.53M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$9.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $2.45M derived: sum of 2 quarters · filed 2018-03-08 | -$5.81M derived: sum of 3 quarters · filed 2018-03-08 | -$18.45M 10-K · filed 2018-03-08 |
| 2017-09-30 | $12.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $4.13M derived: sum of 2 quarters · filed 2017-11-08 | -$8.51M 10-Q · filed 2017-11-08 | -$9.59M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | -$8.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$20.90M 10-Q · filed 2017-08-03 | -$21.97M derived: sum of 3 quarters · filed 2018-03-08 | -$26.18M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | -$12.64M 10-Q · filed 2017-05-04 | -$13.71M derived: sum of 2 quarters · filed 2018-03-08 | -$17.93M derived: sum of 3 quarters · filed 2018-03-08 | -$151.33M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | -$1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$5.29M derived: sum of 2 quarters · filed 2018-03-08 | -$138.69M derived: sum of 3 quarters · filed 2018-03-08 | -$19.39M 10-K · filed 2018-03-08 |
| 2016-09-30 | -$4.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$137.62M derived: sum of 2 quarters · filed 2017-11-08 | -$18.32M 10-Q · filed 2017-11-08 | -$14.09M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$133.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$14.11M 10-Q · filed 2017-08-03 | -$9.88M derived: sum of 3 quarters · filed 2018-03-08 | $23.49M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $119.30M 10-Q · filed 2017-05-04 | $123.53M derived: sum of 2 quarters · filed 2018-03-08 | $156.89M derived: sum of 3 quarters · filed 2018-03-08 | $148.18M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $37.59M derived: sum of 2 quarters · filed 2018-03-08 | $28.89M derived: sum of 3 quarters · filed 2018-03-08 | -$40.25M 10-K · filed 2018-03-08 |
| 2015-09-30 | $33.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $24.66M derived: sum of 2 quarters · filed 2016-11-10 | -$44.48M 10-Q · filed 2016-11-10 | $62.58M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | -$8.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$77.85M 10-Q · filed 2016-08-11 | $29.22M derived: sum of 3 quarters · filed 2017-03-16 | $26.54M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | -$69.14M 10-Q · filed 2016-05-16 | $37.92M derived: sum of 2 quarters · filed 2017-03-16 | $35.25M derived: sum of 3 quarters · filed 2017-03-16 | |
| 2014-12-31 | $107.06M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $104.39M derived: sum of 2 quarters · filed 2017-03-16 | $112.53M 10-K · filed 2017-03-16 | |
| 2014-09-30 | -$2.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $5.47M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $8.14M 10-Q · filed 2015-08-10 | |||
| 2013-12-31 | -$4.56M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |